KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Invested Capital (2016 - 2025)

Historic Invested Capital for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $9.7 billion.

  • Teva Pharmaceutical Industries' Invested Capital rose 3593.07% to $9.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.7 billion, marking a year-over-year increase of 3593.07%. This contributed to the annual value of $9.7 billion for FY2025, which is 3593.07% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Invested Capital stood at $9.7 billion, which was up 3593.07% from $7.3 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Invested Capital's 5-year high stood at $14.8 billion during Q2 2021, with a 5-year trough of $6.7 billion in Q1 2025.
  • Its 5-year average for Invested Capital is $10.3 billion, with a median of $9.8 billion in 2023.
  • Examining YoY changes over the last 5 years, Teva Pharmaceutical Industries' Invested Capital showed a top increase of 3593.07% in 2025 and a maximum decrease of 3690.46% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Invested Capital (Quarter) stood at $12.7 billion in 2021, then dropped by 15.49% to $10.7 billion in 2022, then dropped by 8.49% to $9.8 billion in 2023, then decreased by 26.91% to $7.2 billion in 2024, then soared by 35.93% to $9.7 billion in 2025.
  • Its Invested Capital was $9.7 billion in Q4 2025, compared to $7.3 billion in Q3 2025 and $7.3 billion in Q2 2025.